NCT01628445View on ClinicalTrials.gov

Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin

PHASE3TerminatedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Type 2 Diabetes
Interventions
DRUG

liraglutide

liraglutide titrated to 1.8 mg sc daily

DRUG

placebo injection

placebo injected sc daily volume equal to active comparator

Trial Locations (1)

R3E3P4

Winnipeg Regional Health Authority Health Sciences Centre Winnipeg Diabetes Research Group, Winnipeg

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

University of Manitoba

OTHER

NCT01628445 - Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin | Biotech Hunter | Biotech Hunter